Market Research Report
Triple Analysis: Melanoma, Apoptosis and Protein Kinase Inhibitors
|Published by||BioSeeker Group AB||Product code||227487|
|Published||Content info||5334 Pages
Delivery time: 1-2 business days
|Triple Analysis: Melanoma, Apoptosis and Protein Kinase Inhibitors|
|Published: June 12, 2013||Content info: 5334 Pages||
This triple analysis focuses on cancer drug development strategies in Melanoma and by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.
Below is a short synopsis of each part included in this report:
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:
This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.